These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 37766133)

  • 21. Number of averted COVID-19 cases and deaths attributable to reduced risk in vaccinated individuals in Japan.
    Kayano T; Sasanami M; Kobayashi T; Ko YK; Otani K; Suzuki M; Nishiura H
    Lancet Reg Health West Pac; 2022 Nov; 28():100571. PubMed ID: 35971514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decrease in COVID-19 adverse outcomes in adults during the Delta and Omicron SARS-CoV-2 waves, after vaccination in Mexico.
    Domínguez-Ramírez L; Solis-Tejeda I; Ayon-Aguilar J; Mayoral-Ortiz A; Sosa-Jurado F; Pelayo R; Santos-López G; Cortes-Hernandez P
    Front Public Health; 2022; 10():1010256. PubMed ID: 36176536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Herd immunity induced by COVID-19 vaccination programs and suppression of epidemics caused by the SARS-CoV-2 Delta variant in China.
    Liu H; Zhang J; Cai J; Deng X; Peng C; Chen X; Yang J; Wu Q; Chen X; Chen Z; Zheng W; Viboud C; Zhang W; Ajelli M; Yu H
    medRxiv; 2021 Sep; ():. PubMed ID: 34341803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
    Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
    Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020-March 2022.
    Yamayoshi S; Iwatsuki-Horimoto K; Okuda M; Ujie M; Yasuhara A; Murakami J; Duong C; Hamabata T; Ito M; Chiba S; Kobayashi R; Takahashi S; Mitamura K; Hagihara M; Shibata A; Uwamino Y; Hasegawa N; Ebina T; Izumi A; Kato H; Nakajima H; Sugaya N; Seki Y; Iqbal A; Kamimaki I; Yamazaki M; Kawaoka Y; Furuse Y
    Emerg Infect Dis; 2022 Nov; 28(11):2198-2205. PubMed ID: 36198306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous manifestations of SARS-CoV-2 infection during the Delta and Omicron waves in 348 691 UK users of the UK ZOE COVID Study app.
    Visconti A; Murray B; Rossi N; Wolf J; Ourselin S; Spector TD; Freeman EE; Bataille V; Falchi M
    Br J Dermatol; 2022 Dec; 187(6):900-908. PubMed ID: 35869671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review.
    Arabi M; Al-Najjar Y; Sharma O; Kamal I; Javed A; Gohil HS; Paul P; Al-Khalifa AM; Laws S; Zakaria D
    BMC Infect Dis; 2023 Jun; 23(1):432. PubMed ID: 37365490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of age structure and vaccine prioritization on COVID-19 in West Africa.
    Taboe HB; Asare-Baah M; Yesmin A; Ngonghala CN
    Infect Dis Model; 2022 Dec; 7(4):709-727. PubMed ID: 36097593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimating infection fatality risk and ascertainment bias of COVID-19 in Osaka, Japan from February 2020 to January 2022.
    Zhang T; Nishiura H
    Sci Rep; 2023 Apr; 13(1):5540. PubMed ID: 37016060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology of coronavirus disease 2019 (COVID-19) in Japan during the first and second waves.
    Kinoshita R; Jung SM; Kobayashi T; Akhmetzhanov AR; Nishiura H
    Math Biosci Eng; 2022 Apr; 19(6):6088-6101. PubMed ID: 35603392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Critical immune and vaccination thresholds for determining multiple influenza epidemic waves.
    Matrajt L; Longini IM
    Epidemics; 2012 Mar; 4(1):22-32. PubMed ID: 22325011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Surveillance Metrics for Alerting Community-Acquired Outbreaks of Emerging SARS-CoV-2 Variants Using Imported Case Data: Bayesian Markov Chain Monte Carlo Approach.
    Yen AM; Chen TH; Chang WJ; Lin TY; Jen GH; Hsu CY; Wang ST; Dang H; Chen SL
    JMIR Public Health Surveill; 2022 Nov; 8(11):e40866. PubMed ID: 36265134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changing Epidemiology of COVID-19 in Children and Adolescents Over Four Successive Epidemic Waves in South Africa, 2020-2022.
    Chiwandire N; Jassat W; Groome M; Kufa T; Walaza S; Wolter N; von Gottberg A; Zar HJ; Reubenson G; Tempia S; Ebonwu J; Govender N; Ntshoe G; Shonhiwa AM; Blumberg L; Cohen C
    J Pediatric Infect Dis Soc; 2023 Apr; 12(3):128-134. PubMed ID: 36648247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa.
    Davies MA; Morden E; Rousseau P; Arendse J; Bam JL; Boloko L; Cloete K; Cohen C; Chetty N; Dane P; Heekes A; Hsiao NY; Hunter M; Hussey H; Jacobs T; Jassat W; Kariem S; Kassanjee R; Laenen I; Roux SL; Lessells R; Mahomed H; Maughan D; Meintjes G; Mendelson M; Mnguni A; Moodley M; Murie K; Naude J; Ntusi NAB; Paleker M; Parker A; Pienaar D; Preiser W; Prozesky H; Raubenheimer P; Rossouw L; Schrueder N; Smith B; Smith M; Solomon W; Symons G; Taljaard J; Wasserman S; Wilkinson RJ; Wolmarans M; Wolter N; Boulle A
    Int J Infect Dis; 2023 Feb; 127():63-68. PubMed ID: 36436752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mathematical assessment of the role of waning and boosting immunity against the BA.1 Omicron variant in the United States.
    Safdar S; Ngonghala CN; Gumel AB
    Math Biosci Eng; 2023 Jan; 20(1):179-212. PubMed ID: 36650762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2 Infection upon Leaving the Tokyo 2020 Olympic and Paralympic Games.
    Urashima M; Takao H; Sakano T; Takeshita K; Yoshida M; Nakazawa Y; Kawai M; Murayama Y
    Intern Med; 2022 Dec; 61(24):3659-3666. PubMed ID: 36198605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 infection-induced immunity reduces rates of reinfection and hospitalization caused by the Delta or Omicron variants.
    de La Vega MA; Polychronopoulou E; Xiii A; Ding Z; Chen T; Liu Q; Lan J; Nepveu-Traversy ME; Fausther-Bovendo H; Zaidan MF; Wong G; Sharma G; Kobinger GP
    Emerg Microbes Infect; 2023 Dec; 12(1):e2169198. PubMed ID: 36655944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Not all fun and games: Potential incidence of SARS-CoV-2 infections during the Tokyo 2020 Olympic Games.
    Linton NM; Jung SM; Nishiura H
    Math Biosci Eng; 2021 Nov; 18(6):9685-9696. PubMed ID: 34814363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.